Key Takeaways IDEXX stock has risen 56.2% year to date, far outpacing its industry and the S&P 500.IDEXX's international CAG diagnostic revenues rose 11% in Q2, with strong gains in consumables.IDXX's cloud-native platforms like ezyVet, Neo and Vello delivered double-digit growth in Q2.IDEXX Laboratories (IDXX) has witnessed strong momentum year to date. Shares of the company have risen 56.2%, outperforming the 6.8% decline of the industry during the same time frame. The S&P 500 composite has increased 9.8% ...